Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Tesamorelin vs Testosterone Replacement for Andropause

Primary Target Restores pulsatile GH secretion to reduce visceral adipose tissue and improve insulin sensitivity Elevates serum testosterone to address hypogonadal symptoms (libido, mood, energy, muscle maintenance) Tesamorelin addresses metabolic dysfunction;

This comparison does not assign a generated winner or score.

  • Primary Target
  • Restores pulsatile GH secretion to reduce visceral adipose tissue and improve insulin sensitivity
  • Elevates serum testosterone to address hypogonadal symptoms (libido, mood, energy, muscle maintenance)
  • Tesamorelin addresses metabolic dysfunction; TRT addresses androgen deficiency. They target different andropause pathologies and are often complementary rather than interchangeable
  • Effect on Visceral Fat
  • 15–20% VAT reduction at 26 weeks without significant subcutaneous fat loss
  • Modest VAT reduction (5–8%) if hypogonadism was contributing to fat accumulation, but not selective for visceral depots
  • Tesamorelin is the only FDA-studied intervention that selectively targets VAT without requiring caloric restriction or significant subcutaneous fat loss
  • Impact on Lean Mass
  • Neutral to slight increase (1–2kg). Preserves muscle during VAT reduction
  • Significant increase (3–5kg over 12 months) with resistance training. Directly anabolic
  • TRT builds muscle; tesamorelin preserves it during metabolic correction. Men seeking lean mass gains need TRT, not tesamorelin alone
  • Insulin Sensitivity
  • Improves insulin sensitivity and reduces fasting triglycerides despite GH's diabetogenic reputation. The VAT reduction outweighs the gluconeogenic effect
  • Variable. Can improve if hypogonadism was driving insulin resistance, but supraphysiological dosing can worsen glucose metabolism
  • Tesamorelin's pulsatile GH pattern avoids the sustained receptor activation that causes insulin resistance with exogenous GH. TRT's metabolic benefit depends on baseline testosterone levels
  • Administration
  • Daily subcutaneous injection (2mg reconstituted peptide). Requires consistent timing and refrigerated storage
  • Weekly or biweekly intramuscular injection (cypionate, enanthate) or daily transdermal application. Longer half-life allows flexible dosing
  • Tesamorelin requires stricter adherence and storage discipline; TRT offers more forgiving administration schedules
  • Bottom Line
  • Best for men whose primary concern is visceral adiposity, metabolic syndrome markers (elevated triglycerides, insulin resistance), and abdominal fat resistant to diet. Especially if testosterone is within reference range
  • Best for men with confirmed hypogonadism (total T <300 ng/dL), loss of libido, fatigue, and muscle wasting. Metabolic benefits are secondary to androgen restoration
  • Most men 45–55 benefit from both if labs show low testosterone AND elevated VAT. Tesamorelin corrects the metabolic component TRT doesn't address
  • The common mistake we see: assuming TRT will resolve the visceral fat issue because 'low testosterone causes fat gain'. It doesn't work that way. Testosterone influences where fat is stored, but declining GH is what allows visceral depots to expand unchecked. A man with borderline-low testosterone (350 ng/dL) and 120cm waist circumference often benefits more from tesamorelin than from TRT alone, because the metabolic dysfunction is GH-mediated, not androgen-mediated.
More references

Related material